Showing results (231-240 of 260) with videos related to

Sort By:
Pageof 26
Liver Cancer|October 12, 2019
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score AnalysisDominik Bettinger, David J Pinato, Michael Schultheiss, et al.
Clinical and Translational Radiation Oncology|May 20, 2024
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)Sebastian H Maier, Stephan Schönecker, Vasiliki Anagnostatou, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 18, 2023
The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenograftsAnnett Linge, Shivaprasad Patil, Marianne Grosser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2018
A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV InfectionJulia Hess, Kristian Unger, Cornelius Maihoefer, et al.
The Pharmacogenomics Journal|June 18, 2020
ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapyMaja Guberina, Ali Sak, Christoph Pöttgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2018
Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapyStefan Schmidt, Annett Linge, Alex Zwanenburg, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 11, 2026
A tumor DNA-Methylome derived signature of Hypoxia Identifies HPV-negative head and neck cancer patients at risk for distant metastasis after postoperative radiochemotherapy (PORT-C)Bouchra Tawk, Gordana Halec, Katrin Rein, et al.
The Lancet. Oncology|December 22, 2025
O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trialAnca-Ligia Grosu, Wolfgang A Weber, Erika Graf, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 11, 2023
PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/mlNantia Solomonidou, Daphnie Germanou, Iosif Strouthos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 24, 2024
Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial ResultsAntonin Levy, Sonja Adebahr, Coen Hurkmans, et al.
Pageof 26